

Medical Policy:

Adcetris® (brentuximab vedotin) Intravenous

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.130	February 10, 2025	

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Adcetris (brentuximab vedotin): is a CD30-directed antibody-drug conjugate (ADC) consisting of 3 components: the chimeric IgG1 antibody cAC10 which is specific for human CD30; the microtubule disrupting agent MMAE; and a protease-cleavable linker that covalently attaches MMAE to cAC10. The anticancer activity of brentuximab vedotin is presumed to be due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex and the release of MMAE via proteolytic cleavage. The microtubule disrupting agent MMAE binds to tubulin, disrupting the microtubule network which leads to cell cycle arrest and apoptotic death of the cells.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

- Treatment of previously untreated Pediatric Classical Hodgkin Lymphoma (cHL) as a component of Bv-AVE-PC (brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) has a maximum of 5 doses.
- Pediatric cHL as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) has a maximum of 2 cycles (6 doses).

- Pediatric cHL as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) has a maximum of 4 cycles (8 doses).
- Adult cHL in combination with nivolumab has a maximum of 8 doses.
- Pediatric cHL in combination with nivolumab has a maximum of 4 doses.
- Pediatric and Adult cHL in combination with bendamustine has a maximum of 6 doses.
- Adult cHL in combination with ifosfamide, carboplatin, and etoposide (ICE) has a maximum of 4 doses.
- Adult cHL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) has a maximum of 6 doses.
- Adult cHL post-auto HSCT, Primary Cutaneous Lymphomas (excluding use with bendamustine or CHP), single agent use for T-Cell Lymphomas (excluding Systemic ALCL), and Pediatric cHL (excluding use with Bv-AVE-PC, AEPA, CAPDAC, nivolumab, or bendamustine) has a maximum of 16 doses.
- Treatment of previously untreated Adult Stage III or IV cHL in combination with AVD (doxorubicin, vinblastine, and dacarbazine) has a maximum of 12 doses.
- Treatment of T-cell lymphomas in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) has a maximum of 8 doses.
- Primary Cutaneous Lymphomas in combination with CHP for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders has a maximum of 8 doses.

Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

Classical Hodgkin Lymphoma:

- 1350 billable units every 84 days

All other indications:

- 200 billable units every 21 days

Guideline

I. INITIAL APPROVAL CRITERIA

1. Adult Classic Hodgkin Lymphoma (cHL) † ‡ Φ

a. Used as single agent therapy; **AND**

- Used as consolidation/maintenance therapy post-autologous hematopoietic stem cell transplant (auto-HSCT) in patients at high risk* for relapse or progression † ‡; **OR**
- Patient has relapsed disease after failure of auto-HSCT or after failure of at least 2 (two) prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates †; **OR**
- Used as subsequent systemic therapy for primary refractory or relapsed disease ‡; **OR**

b. Used in combination with bendamustine; **AND**

- Used as subsequent systemic therapy for primary refractory or relapsed disease ‡; **OR**

c. Used in combination with nivolumab; **AND**

- Used as subsequent systemic therapy for primary refractory or relapsed disease ‡; **OR**
- Used as primary treatment for patients of any age who are not candidates for anthracycline therapy; **AND**

- Used in combination with involved-site radiation therapy (IRST); **OR**

d. Used in combination with dacarbazine; **AND**

- Used as primary treatment in patients of any age who are not candidates for anthracycline therapy; **AND**

- Used in combination with involved-site radiation therapy (IRST); **OR**

e. Used in combination with ifosfamide, carboplatin, and etoposide (ICE); **AND**

- i. Used as subsequent systemic therapy for primary refractory or relapsed disease ‡; **OR**
- f. Used in combination with doxorubicin, vinblastine, and dacarbazine (AVD); **AND**
 - i. Used as initial therapy for previously untreated stage III or IV disease †; **OR**
 - ii. Used as primary treatment for stage I-II unfavorable disease ‡; **AND**
 - 1. Patient is 18-60 years of age; **OR**
 - 2. Patient is > 60 years of age and is a candidate for anthracycline therapy; **OR**
- g. Used in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD); **AND**
 - i. Used as primary treatment in patients 18-61 years of age; **AND**
 - 1. Patient has stage I/II unfavorable disease; **OR**
 - 2. Patient has stage III-IV disease

***High risk for relapse or progression may be defined as:**

- Refractory disease, disease relapse within 12 months, or relapse ≥12 months with extranodal disease following frontline therapy; **OR**
- Two or more of the following: remission duration <1 year, extranodal involvement, FDG-PET+ response at time of transplant, B symptoms, and/or >1 second-line/subsequent therapy regimen

2. Pediatric Classic Hodgkin Lymphoma (cHL) † ‡ Φ

- a. Patient is ≤ 18 years of age*; **AND**
- b. Used in combination with bendamustine, nivolumab, or gemcitabine; **AND**
 - i. Used in patients heavily pretreated with platinum or anthracycline-based chemotherapy; **OR**
 - ii. Used if a decrease in cardiac function is observed; **OR**
- c. Used as maintenance therapy following high-dose therapy and autologous stem cell rescue (HDT/ASCR); **AND**
 - i. Used as a single agent for relapsed or refractory high-risk disease (i.e., progressive disease, refractory disease, or relapse within 1 year of original diagnosis); **OR**
- d. Used as primary therapy in patients with high-risk disease**; **AND**
 - i. Used as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) regimen; **OR**
 - ii. Used as a component of Bv-AVE-PC (brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) †; **AND**
 - 1. Patient is at least 2 years of age; **OR**
- e. Used as additional treatment following primary treatment with AEPA regimen in patients with high-risk disease**; **AND**
 - i. Used as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) regimen

**Pediatric Hodgkin Lymphoma may be applicable to adolescent and young adult (AYA) patients up to the age of 39 years.*

***High risk disease may be defined as: Stage IIB with bulk or E-lesions (involvement of extra-lymphatic tissue), Stage IIIA with E-lesions, or Stage IIIB or IV disease.*

3. Pediatric Aggressive Mature B-Cell Lymphomas (Primary Mediastinal Large B-Cell Lymphoma) ‡

- a. Patient is ≤ 18 years of age*; **AND**
- b. Used in combination with nivolumab or pembrolizumab; **AND**
- c. Used as consolidation/additional therapy if a partial response was achieved after therapy for relapsed or refractory disease

**Pediatric Aggressive Mature B-Cell Lymphoma may be applicable to adolescent and young adult (AYA) patients older than 18 years of age and less than 39 years of age, who are treated in the pediatric oncology setting.*

4. T-Cell Lymphomas

- a. Peripheral T-Cell Lymphomas (PTCL)
 - i. Used as a single agent for relapsed or refractory disease as subsequent OR as initial palliative intent therapy for one of the following:
 - 1. Systemic Anaplastic Large Cell Lymphoma (sALCL) † Φ
 - 2. Peripheral T-Cell Lymphoma not otherwise specified (PTCL-NOS) ‡ Φ
 - 3. Angioimmunoblastic T-cell Lymphoma (AITL) ‡ Φ; **OR**
 - ii. Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) as initial therapy for previously untreated:
 - 1. Systemic Anaplastic Large Cell Lymphoma (sALCL) † Φ
 - 2. Peripheral T-Cell Lymphoma not otherwise specified (PTCL-NOS) † Φ
 - 3. Angioimmunoblastic T-cell Lymphoma (AITL) † Φ
 - 4. Enteropathy-Associated T-cell Lymphoma (EATL) ‡ Φ
 - 5. Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL) ‡
 - 6. Nodal Peripheral T-cell Lymphoma with TFH phenotype (PTCL, TFH) ‡
 - 7. Follicular T-cell Lymphoma (FTCL) ‡
- b. Breast-Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) ‡
 - i. Used as adjuvant therapy as a single agent or in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**
 - 1. Patient has localized disease to the capsule, implant, or breast with residual disease following an incomplete excision or partial capsulectomy, if either node positive or radiation therapy is not feasible; **OR**
 - 2. Patient has extended disease (stage II-IV); **OR**
 - ii. Used as subsequent therapy for relapsed or refractory disease as a single agent
- c. Adult T-Cell Leukemia/Lymphoma ‡ Φ
 - i. Used as a single agent; **AND**
 - 1. Used as subsequent therapy for nonresponders to first-line therapy for chronic high risk, acute, or lymphoma subtypes; **OR**
 - ii. Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**
 - 1. Used as first-line therapy for chronic high risk, acute or lymphoma subtypes; **OR**
 - 2. Used as continued treatment in responders to first-line therapy for acute or lymphoma subtypes; **OR**
 - 3. Used as additional therapy for nonresponders to first-line therapy for chronic low risk or smoldering symptomatic subtype; **OR**
 - 4. Used as additional therapy for nonresponders to first-line therapy with zidovudine and interferon for chronic high risk subtype; **OR**
 - 5. Used as additional therapy (if not previously used) for nonresponders to first-line therapy for acute subtype
- d. Extranodal NK/T-Cell Lymphoma ‡ Φ
 - i. Used as a single agent for relapsed or refractory disease; **AND**
 - ii. Used following additional therapy with an alternate combination chemotherapy regimen (asparaginase-based) not previously used
- e. Hepatosplenic T-Cell Lymphoma ‡
 - i. Used as single-agent therapy; **AND**
 - ii. Used for refractory disease as subsequent therapy after 2 (two) first-line therapy regimens

5. Primary Cutaneous Lymphomas

- a. Mycosis Fungoides (MF) † Φ/Sezary Syndrome (SS) ‡

- i. Used as single agent systemic therapy; **AND**
 - 1. Used as primary therapy (*excluding use in patients with stage IA disease*); **OR**
 - 2. Used as subsequent therapy; **OR**
- ii. Used in combination with bendamustine; **AND**
 - 1. Used as primary treatment; **AND**
 - a. Patient has stage IVA2 non-Sezary or stage IVB visceral disease (solid organ); **OR**
 - b. Patient has generalized cutaneous or extracutaneous lesions with large cell transformation (LCT); **AND**
 - i. Used in combination with skin-directed therapy; **OR**
 - 2. Used as subsequent treatment; **AND**
 - a. Used for disease refractory to multiple previous therapies; **AND**
 - b. Used in combination with skin-directed therapy; **AND**
 - i. Patient has stage IIB Mycosis Fungoides with generalized tumor lesions; **OR**
 - ii. Patient has stage III Mycosis Fungoides; **OR**
 - iii. Patient has limited cutaneous lesions with large cell transformation (LCT); **OR**
 - c. Used for relapsed or persistent disease; **AND**
 - i. Patient has stage IVA2 non-Sezary or stage IVB visceral disease (solid organ); **OR**
 - ii. Patient has LCT with generalized cutaneous or extracutaneous lesions; **AND** Used in combination with skin-directed therapy
- b. Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders † Φ
 - i. Used as a single agent; **AND**
 - 1. Patient has primary cutaneous anaplastic large cell lymphoma (pcALCL) † Φ; **OR**
 - 2. Patient has cutaneous ALCL with regional node (N1) (*excludes systemic ALCL*); **OR**
 - 3. Patient has lymphomatoid papulosis (LyP) with extensive lesions that is relapsed or refractory to treatment options (e.g., clinical trial, observation, retreatment with primary treatment, or treatment with alternative regimen not used for primary treatment); **OR**
 - ii. Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**
 - 1. Patient has cutaneous ALCL with regional node (N1) (*excludes systemic ALCL*)

6. **B-Cell Lymphomas ‡**

- a. Diffuse Large B-Cell Lymphoma (DLBCL) or High Grade B-Cell Lymphomas
 - i. Used as a single agent as subsequent therapy; **AND**
 - 1. Used for relapsed disease >12 months after completion of first-line therapy if no intention to proceed to transplant; **OR**
 - 2. Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of first-line therapy*; **OR**
 - 3. Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease; **OR**
 - ii. Used in combination with lenalidomide and rituximab; **AND**
 - 1. Used as third-line and subsequent treatment for partial response, relapsed, progressive or refractory disease
- b. HIV-Related B-Cell Lymphomas (i.e., HIV-related DLBCL, primary effusion lymphoma, or HHV8-positive DLBCL, not otherwise specified or plasmablastic lymphoma)

- i. Used as single agent for relapsed plasmablastic lymphoma; **OR**
- ii. Used as a single agent as subsequent therapy; **AND**
 - 1. Used for relapsed disease >12 months after completion of first-line therapy if no intention to proceed to transplant; **OR**
 - 2. Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of first-line therapy*; **OR**
 - 3. Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease; **OR**
- iii. Used in combination with lenalidomide and rituximab; **AND**
 - 1. Used as third-line and subsequent treatment for partial response, relapsed, progressive or refractory disease (*excludes use in plasmablastic lymphoma*)
- c. Post-Transplant Lymphoproliferative Disorders (PTLD)
 - i. Used as a single agent as subsequent therapy for monomorphic B-cell type disease; **AND**
 - 1. Used for relapsed disease >12 months after completion of initial treatment with chemoimmunotherapy; **OR**
 - 2. Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of initial treatment with chemoimmunotherapy*; **OR**
 - 3. Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease; **OR**
 - ii. Used in combination with lenalidomide and rituximab; **AND**
 - 1. Used as third-line and subsequent treatment for partial response, relapsed, progressive or refractory disease

Note: Only applies to patients who are non-candidates for CAR T-cell therapy.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ◊ Orphan Drug

Limitations/Exclusions

Adcetris is not considered medically necessary for when any of the following selection criteria is met:

1. Disease progression while on Adcetris (brentuximab vedotin).
2. Avoid use in severe renal impairment (creatinine clearance less than 30 mL/min) or moderate to severe hepatic impairment (Child-Pugh B or C).
3. Dosing exceeds single dose limit of Adcetris (brentuximab vedotin) 180 mg.
4. Treatment with Adcetris (brentuximab vedotin) exceeds the maximum duration limit of 16 cycles (12 doses for first line treatment of Hodgkin's Disease).
5. Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)

II. RENEWAL CRITERIA

1. Patient continues to meet INITIAL approval criteria **AND**
2. Duration of authorization has not been exceeded **AND**
3. Disease response with treatment defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
4. Absence of unacceptable toxicity from the drug **AND**

Note: Examples of unacceptable toxicity include: peripheral neuropathy, anaphylaxis and infusion reactions, hematologic toxicities (thrombocytopenia, neutropenia, and anemia), serious infections, opportunistic infections,

tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, serious dermatologic reactions, gastrointestinal complications, uncontrolled hyperglycemia, etc.

5. Patient has been evaluated for the presence of progressive multifocal leukoencephalopathy (PML) and has been found to be negative.

Dosage/Administration

Dosing	
Adult cHL	<p><u>Previously untreated stage III or IV in combination with doxorubicin, vinblastine, and dacarbazine (AVD)</u> Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity</p> <p><u>Consolidation/maintenance post auto HSCT as a single agent</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity</p> <p><u>Primary refractory or relapsed disease in combination with bendamustine</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 doses</p> <p><u>Primary refractory or relapsed disease in combination with nivolumab</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 8 doses</p> <p><u>Primary refractory or relapsed disease in combination with ifosfamide, carboplatin, and etoposide (ICE)</u> Administer 1.5 mg/kg (up to 150 mg) by intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 4 doses</p> <p><u>Primary therapy in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD)</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 cycles</p> <p><u>All other treatment settings/regimens:</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity</p>
Primary Cutaneous Lymphomas	<p><u>Single agent therapy for Mycosis Fungoides (MF)/Sezary Syndrome (SS)</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity</p> <p><u>In combination with bendamustine for Mycosis Fungoides (MF)/Sezary Syndrome (SS)</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity</p> <p><u>Single agent therapy for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity</p> <p><u>In combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders</u></p>

	Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 8 cycles
Pediatric cHL	<p><u>Previously untreated high-risk disease in combination with Bv-AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 5 doses</p> <p><u>Primary therapy for high-risk disease as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin)</u> Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1, 8, 15 every 28 days for 2 cycles</p> <p><u>Additional treatment as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine)</u> Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1 and 8 every 21 days for 4 cycles</p> <p><u>In combination with nivolumab</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 4 doses</p> <p><u>In combination with bendamustine</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 doses</p> <p><u>All other treatment settings/regimens</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity</p>
T-Cell Lymphomas	<p><u>In combination with cyclophosphamide, doxorubicin, and prednisone (CHP)</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 to 8 doses</p> <p><u>Single agent treatment for relapsed Systemic ALCL:</u> Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity</p>
B-Cell Lymphomas & Pediatric Aggressive Mature B-Cell lymphomas	Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity

Applicable Procedure Codes

Code	Description
J9042	Injection, brentuximab vedotin, 1 mg, 1 billable unit = 1 mg

Applicable NDCs

Code	Description
51144-0050-xx	Adcetris single use vial; 50 mg powder for injection

ICD-10 Diagnoses

Code	Description
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes
C81.27	Mixed cellularity Hodgkin lymphoma, spleen
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other Hodgkin lymphoma unspecified site
C81.71	Other Hodgkin lymphoma lymph nodes of head, face, and neck
C81.72	Other Hodgkin lymphoma intrathoracic lymph nodes
C81.73	Other Hodgkin lymphoma intra-abdominal lymph nodes
C81.74	Other Hodgkin lymphoma lymph nodes of axilla and upper limb

C81.75	Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.76	Other Hodgkin lymphoma intrapelvic lymph nodes
C81.77	Other Hodgkin lymphoma spleen
C81.78	Other Hodgkin lymphoma lymph nodes of multiple sites
C81.79	Other Hodgkin lymphoma extranodal and solid organ sites
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C83.30	Diffuse large B-cell lymphoma unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma lymph nodes of multiple sites
C83.398	Diffuse large B-cell lymphoma of other extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.90	Non-follicular (diffuse) lymphoma, unspecified site
C83.91	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes
C83.94	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb
C83.95	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified spleen
C83.98	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites
C83.99	Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites
C84.00	Mycosis fungoides, unspecified site

C84.01	Mycosis fungoides, lymph nodes of head, face and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.10	Sézary disease, unspecified site
C84.11	Sézary disease, lymph nodes of head, face, and neck
C84.12	Sézary disease, intrathoracic lymph nodes
C84.13	Sézary disease, intra-abdominal lymph nodes
C84.14	Sézary disease, lymph nodes of axilla and upper limb
C84.15	Sézary disease, lymph nodes of inguinal region and lower limb
C84.16	Sézary disease, intrapelvic lymph nodes
C84.17	Sézary disease, spleen
C84.18	Sézary disease, lymph nodes of multiple sites
C84.19	Sézary disease, extranodal and solid organ sites
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face and neck
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region of lower limb
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes
C84.47	Peripheral T-cell lymphoma, not classified, spleen
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face and neck
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face and neck
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes
C84.73	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen

C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
C84.7A	Anaplastic large cell lymphoma, ALK-negative, breast
C84.90	Mature T/NK-cell lymphomas, unspecified site
C84.91	Mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C84.92	Mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.93	Mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.94	Mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.95	Mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.96	Mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.97	Mature T/NK-cell lymphomas, spleen
C84.98	Mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.99	Mature T/NK-cell lymphomas, extranodal and solid organ sites
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature T/NK-cell lymphomas, spleen
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C85.10	Unspecified B-cell lymphoma unspecified site
C85.11	Unspecified B-cell lymphoma lymph nodes of head, face, and neck
C85.12	Unspecified B-cell lymphoma intrathoracic lymph nodes
C85.13	Unspecified B-cell lymphoma intra-abdominal lymph nodes
C85.14	Unspecified B-cell lymphoma lymph nodes of axilla and upper limb
C85.15	Unspecified B-cell lymphoma lymph nodes of inguinal region and lower limb
C85.16	Unspecified B-cell lymphoma intrapelvic lymph nodes
C85.17	Unspecified B-cell lymphoma spleen
C85.18	Unspecified B-cell lymphoma lymph nodes of multiple sites
C85.19	Unspecified B-cell lymphoma extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes

C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C86.00	Extranodal NK/T-cell lymphoma, nasal type not having achieved remission
C86.10	Hepatosplenic T-cell lymphoma not having achieved remission
C86.20	Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission
C86.50	Angioimmunoblastic T-cell lymphoma not having achieved remission
C86.60	Primary cutaneous CD30-positive T-cell proliferations not having achieved remission
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated) in remission
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)
Z85.71	Personal history of Hodgkin lymphoma

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	2/10/2025	Update Initial criteria to include † FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Addition of Dosage/Administration chart, Lengths of Authorization Removed C81.0 Nodular lymphocyte predominant HL Addition of
		C81.30 Lymphocyte depleted Hodgkin lymphoma, unspecified site
		C81.31 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
		C81.32 Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
		C81.33 Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
		C81.34 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
		C81.35 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
		C81.36 Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
		C81.37 Lymphocyte depleted Hodgkin lymphoma, spleen
		C81.38 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
		C81.39 Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
		C81.40 Lymphocyte-rich Hodgkin lymphoma, unspecified site
		C81.41 Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
		C81.42 Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes

		C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
		C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
		C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
		C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes
		C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen
		C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites
		C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
		C81.70	Other Hodgkin lymphoma unspecified site
		C81.71	Other Hodgkin lymphoma lymph nodes of head, face, and neck
		C81.72	Other Hodgkin lymphoma intrathoracic lymph nodes
		C81.73	Other Hodgkin lymphoma intra-abdominal lymph nodes
		C81.74	Other Hodgkin lymphoma lymph nodes of axilla and upper limb
		C81.75	Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb
		C81.76	Other Hodgkin lymphoma intrapelvic lymph nodes
		C81.77	Other Hodgkin lymphoma spleen
		C81.78	Other Hodgkin lymphoma lymph nodes of multiple sites
		C81.79	Other Hodgkin lymphoma extranodal and solid organ sites
		C81.90	Hodgkin lymphoma, unspecified, unspecified site
		C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck
		C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
		C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
		C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
		C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
		C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
		C81.97	Hodgkin lymphoma, unspecified, spleen
		C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
		C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
		C83.30	Diffuse large B-cell lymphoma unspecified site
		C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
		C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes
		C83.33	Diffuse large B-cell lymphoma intra-abdominal lymph nodes
		C83.34	Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb

		C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
		C83.36	Diffuse large B-cell lymphoma intrapelvic lymph nodes
		C83.37	Diffuse large B-cell lymphoma, spleen
		C83.38	Diffuse large B-cell lymphoma lymph nodes of multiple sites
		C83.398	Diffuse large B-cell lymphoma of other extranodal and solid organ sites
		C83.80	Other non-follicular lymphoma, unspecified site
		C83.81	Other non-follicular lymphoma, lymph nodes of head, face and neck
		C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
		C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
		C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
		C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
		C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
		C83.87	Other non-follicular lymphoma, spleen
		C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
		C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
		C83.90	Non-follicular (diffuse) lymphoma, unspecified site
		C83.91	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck
		C83.92	Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes
		C83.93	Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes
		C83.94	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb
		C83.95	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb
		C83.96	Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes
		C83.97	Non-follicular (diffuse) lymphoma, unspecified spleen
		C83.98	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites
		C83.99	Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites
		C84.7A	Anaplastic large cell lymphoma, ALK-negative, breast
		C84.90	Mature T/NK-cell lymphomas, unspecified site
		C84.91	Mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
		C84.92	Mature T/NK-cell lymphomas, intrathoracic lymph nodes
		C84.93	Mature T/NK-cell lymphomas, intra-abdominal lymph nodes
		C84.94	Mature T/NK-cell lymphomas, lymph nodes of axilla

			and upper limb
		C84.95	Mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
		C84.96	Mature T/NK-cell lymphomas, intrapelvic lymph nodes
		C84.97	Mature T/NK-cell lymphomas, spleen
		C84.98	Mature T/NK-cell lymphomas, lymph nodes of multiple sites
		C84.99	Mature T/NK-cell lymphomas, extranodal and solid organ sites
		C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
		C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
		C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
		C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
		C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
		C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
		C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
		C84.Z7	Other mature T/NK-cell lymphomas, spleen
		C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
		C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
		C85.10	Unspecified B-cell lymphoma unspecified site
		C85.11	Unspecified B-cell lymphoma lymph nodes of head, face, and neck
		C85.12	Unspecified B-cell lymphoma intrathoracic lymph nodes
		C85.13	Unspecified B-cell lymphoma intra-abdominal lymph nodes
		C85.14	Unspecified B-cell lymphoma lymph nodes of axilla and upper limb
		C85.15	Unspecified B-cell lymphoma lymph nodes of inguinal region and lower limb
		C85.16	Unspecified B-cell lymphoma intrapelvic lymph nodes
		C85.17	Unspecified B-cell lymphoma spleen
		C85.18	Unspecified B-cell lymphoma lymph nodes of multiple sites
		C85.19	Unspecified B-cell lymphoma extranodal and solid organ sites
		C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
		C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck
		C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes

		<table border="1"> <tr> <td>C85.23</td> <td>Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes</td> </tr> <tr> <td>C85.24</td> <td>Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb</td> </tr> <tr> <td>C85.25</td> <td>Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb</td> </tr> <tr> <td>C85.26</td> <td>Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes</td> </tr> <tr> <td>C85.27</td> <td>Mediastinal (thymic) large B-cell lymphoma, spleen</td> </tr> <tr> <td>C85.28</td> <td>Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites</td> </tr> <tr> <td>C85.29</td> <td>Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites</td> </tr> <tr> <td>C85.80</td> <td>Other specified types of non-Hodgkin lymphoma, unspecified site</td> </tr> <tr> <td>C85.81</td> <td>Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck</td> </tr> <tr> <td>C85.82</td> <td>Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes</td> </tr> <tr> <td>C85.83</td> <td>Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes</td> </tr> <tr> <td>C85.84</td> <td>Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb</td> </tr> <tr> <td>C85.85</td> <td>Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb</td> </tr> <tr> <td>C85.86</td> <td>Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes</td> </tr> <tr> <td>C85.87</td> <td>Other specified types of non-Hodgkin lymphoma, spleen</td> </tr> <tr> <td>C85.88</td> <td>Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites</td> </tr> <tr> <td>C85.89</td> <td>Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites</td> </tr> <tr> <td>C86.00</td> <td>Extranodal NK/T-cell lymphoma, nasal type not having achieved remission</td> </tr> <tr> <td>C86.10</td> <td>Hepatosplenic T-cell lymphoma not having achieved remission</td> </tr> <tr> <td>C86.20</td> <td>Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission</td> </tr> </table>	C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck	C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb	C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	C85.87	Other specified types of non-Hodgkin lymphoma, spleen	C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	C86.00	Extranodal NK/T-cell lymphoma, nasal type not having achieved remission	C86.10	Hepatosplenic T-cell lymphoma not having achieved remission	C86.20	Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes																																									
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb																																									
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb																																									
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes																																									
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen																																									
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites																																									
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites																																									
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site																																									
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck																																									
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes																																									
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes																																									
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb																																									
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb																																									
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes																																									
C85.87	Other specified types of non-Hodgkin lymphoma, spleen																																									
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites																																									
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites																																									
C86.00	Extranodal NK/T-cell lymphoma, nasal type not having achieved remission																																									
C86.10	Hepatosplenic T-cell lymphoma not having achieved remission																																									
C86.20	Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission																																									
EmblemHealth & ConnectiCare	4/29/2024	Annual Review: Removed prescribing information link, updated dosing limits, no criteria changes																																								
EmblemHealth & ConnectiCare	8/11/2023	<p>Annual Review:</p> <p>Initial Criteria: Added "Previously Untreated High Risk Classical Hodgkin Lymphoma (cHL) in pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide."</p> <p>Removed "Use in Peripheral T-Cell Lymphomas (PTCL) as second line or subsequent therapy as a single agent or in combination with chemotherapy for relapsed/refractory disease."</p> <p>Limitations/Exclusions: Removed " 18 years of age or younger"</p>																																								

EmblemHealth & ConnectiCare	3/17/2022	Transferred policy to new template
EmblemHealth & ConnectiCare	4/20/2020	<p>Added criteria per FDA Label under Classical Hodgkin Lymphoma :</p> <p>1. For the treatment of adult patients with previously untreated Stage III or IV cHL, in combination with doxorubicin, vinblastine, and dacarbazine</p> <p>Added the following indications and criteria per FDA Label:</p> <p>Peripheral T-Cell Lymphomas (PTCL)</p> <p>a. Adcetris (brentuximab vedotin) is being used for PTCL that is CD30 positive and any of the following:</p> <p>i. First line therapy as a component of brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, prednisone); OR</p> <p>iii. Second line or subsequent therapy as a single agent for relapsed/refractory disease.</p> <p>Limitations/Exclusions (per FDA Label):</p> <p>1. Age Restriction added: 18 years of age or older</p> <p>2. Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)</p>
EmblemHealth & ConnectiCare	7/23/2020	Updated clinical criteria to include CD-expressing mycosis fungoides (MF) to match FDA Labeled indication

References

1. Adcetris prescribing information. Bothell, WA: Seattle Genetics Inc. 2017.
2. Clinical Pharmacology Elsevier Gold Standard. 2018.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2018.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2018.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2018.